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Abstract
Over the past decade, it has become clear that there is an important subset of memory T cells that 
resides in tissues — tissue resident memory T cells (TRM). There is an emerging understanding 
that TRM have a role in human tissue specific immune and inflammatory diseases. Furthermore, 
the nature of the molecular signals that maintain TRM in tissues is the subject of much 
investigation. In addition while it is logical for TRM to be located in barrier tissues at interfaces 
with the environment in human and mouse, TRM have also been found in brain, kidney, joint, and 
other non-barrier tissues in both species. Their biology and behavior make it likely that they play a 
role in chronic relapsing and remitting diseases of both barrier and non-barrier tissues. This review 
will discuss recent understandings of the biology of TRM with a particular focus on their role in 
disease.
Introduction
Memory T cells provide rapid and highly effective protective immunity to previously 
encountered antigens derived from pathogen, tumor, or environmental proteins. It was 
previously thought that T cells consisted of two major subsets: central memory T cells 
(TCM) and effector memory T cells (TEM)1. TCM express the chemokine receptor CCR7 and 
the vascular addressin L selectin (CD62L), permitting them to access and enter lymph nodes 
from blood. TEM express low levels of CCR7 and CD62L but have receptors that allow them 
to access peripheral tissues (e.g., the E selectin ligand Cutaneous Lymphocyte Antigen, or 
CLA) which grants them access to the skin, and α4β7 which is an integrin that allows them 
access to the gut2,3.
Over the past decade, it has become clear that there is another important subset of memory T 
cells—tissue resident memory T cells, or TRM. TRM reside in epithelial barrier tissues at the 
interface between the host and the environment, such as the gastrointestinal tract, respiratory 
tract, reproductive tract, and skin. TRM can respond rapidly to pathogen challenge at these 
sites without recruitment of T cells from the blood4,5. They thus mediate the rapid protective 
immunity that is the hallmark of adaptive immune memory4. TRM in a tissue are enriched 
for T cells specific for pathogens and other antigens that have been encountered previously 
through that barrier epithelium. Thus, the TCR repertoire of skin TRM is different from lung 
TRM, and both are different from gut TRM5. However, TRM are not simply memory T cells 
in an unexpected location; rather, they have a transcriptional program that distinguishes 
them from peripheral blood TEM and TCM 6.
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The cell signaling interactions that maintain TRM in their resident tissues is the subject of 
much investigation. The role of TRM in human tissue specific immune and inflammatory 
diseases is just beginning to be appreciated5. In addition while there is good logic for TRM to 
be stationed at our interfaces with the environment, TRM have also been found in brain, 
kidney, joint, and other non-barrier tissues. TRM that appear in non-barrier tissues have 
similar transcriptional programs7, and their biology and behavior make it likely that they 
play a role in chronic relapsing and remitting diseases of non-barrier tissues.
We will discuss how TRM are generated after an immune response, and review both 
common features of TRM as well as unique features of TRM in various barrier tissues, 
including skin, lung, and GI tract. We will further discuss how TRM may be formed in sterile 
non-barrier tissues like brain and kidney, and will speculate as to the role of TRM in immune 
and inflammatory diseases involving tissues. Finally, the role of TRM in cancer, and the goal 
of generating TRM during vaccination for both infectious diseases and cancer will be 
reviewed. The field is developing at a rapid rate, and new observations are being made on an 
ongoing basis.
TRM generation during an immune response
Naive T cells circulate between blood and lymph nodes, where they remain for 12–24 hours 
before exiting into blood and sampling another lymph node microenvironment8. Naive T 
cells are abundant but highly diverse with regard to T cell repertoire, and hence pathogens to 
which they are targeted, such that naive T cells specific for any given antigen are rare9. 
Dendritic cells are the first to encounter infectious challenge in peripheral tissues, and they 
ferry pathogen fragments to draining lymph nodes where they present processed peptides 
(antigens) to naive T cells. Those T cells that recognize the antigen become activated and 
clonally expand, such that one naive T cell gives rise to tens of thousands of progeny9,10. 
Although all these T cells have the same T cell receptor, the dividing T cells become 
heterogeneous with regard to homing molecules that they express11. Some gain the ability to 
access peripheral tissues, and others will retain the capacity to enter lymph nodes from blood 
(TCM). Effector T cells also acquire new functions that are specific to the pathogen 
encountered; for example, Th1 cells secrete IFNγ production (a cytokine that induces a 
broad range of antiviral factors) in response to viral pathogens and Th17 cell produce IL-17, 
a potent inducer of neutrophil activation and recruitment, in response to bacterial and fungal 
pathogens12.
The anatomic location of the draining lymph node determines expression of tissue homing 
molecules on formerly naive T cells first activated in that microenvironment11,13. Naive T 
cells that are activated in skin draining lymph nodes are induced to express Cutaneous 
Lymphocyte Antigen (CLA, a glycosylated variant of P selectin glycoprotein ligand 
1)2,14–16, a ligand for E selectin, as well as a subset of chemokine receptors that facilitate 
skin homing (e.g., CCR4, CCR6, CCR8, CCR10)17–19. Alternatively, activation of naïve T 
cells in gut draining lymph nodes induces expression of α4β7 integrin20,21, the receptor of 
mucosal addressin cell adhesion molecule (MAdCAM), expressed on post capillary venules 
in intestinal lamina propria22, in addition to distinct chemokine receptors including CCR923 
which binds to CCL25 produced by intestinal epithelium.
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The clonally expanding T cell population includes cells that differentiate into tissue homing 
effector cells, but also cells that retain CD62L and CCR7 and remain more like TCM. These 
latter cells leave the draining lymph node and travel to other lymph nodes, where a subset 
can differentiate to express different tissue homing molecules11. After effector T cells exit 
the lymph node, those with skin homing markers are preferentially trapped by inflamed 
vessels in skin and extravasate into dermis24. These T cells migrate along chemotactic 
gradients to the site of pathogen invasion, where they become activated by antigen, and 
produce cytokines and other effector molecules (e.g., granzymes) that lead to pathogen 
elimination25–27. It is now clear that some of these newly arrived T cells remain in place as 
TRM. This sequence of events can play out again and again, in multiple barrier tissues, over 
the lifetime of an individual, and the result is the accumulation of diverse and largely (but 
not completely) non-overlapping populations of TRM in each barrier tissue4,5. Thus, lung 
contains influenza specific TRM 28–30, gut contains rotavirus specific TRM 31, and skin 
contains candida specific TRM 32,33, and reproductive mucosa contains HSV specific 
TRM 34–37. It was recently shown that the unique naive T cells that give rise to these TRM 
have also given rise to TCM, thus the TRM population in tissue is “duplicated in function” by 
a population of TCM with an identical T cell repertoire38.
The process of TRM formation involves some additional nuances not mentioned above. For 
example, when mouse skin is infected with Vaccinia virus by scarification, effector T cells 
accumulate not only at the vaccinated site, but throughout the skin4, and this was recently 
shown to be true for skin immunization with proteins and haptens 38 Non-inflamed skin 
contains post capillary venules that express low levels of E selectin, chemokines, and 
ICAM-1, all of the requisite molecules for extravasation of skin homing T cells24, allowing 
them to home to uninfected skin sites. In the same fashion, endothelial molecules specific 
for gut homing T cell are expressed on resting lamina propria endothelium22, allowing gut 
homing T cells to home to normal gut. Additionally multiple sequential encounters with a 
pathogen at distinct sites on skin leads to a further accumulation of pathogen specific TRM 
throughout skin; thus more TRM are present for pathogens encountered more frequently4. 
Furthermore, while each naive T cell (and its progeny) has a unique T cell receptor, the 
expanded clone is otherwise heterogeneous. TCM have limited effector function or protective 
capacity themselves4, but have the potential to replenish the TRM compartment upon 
activation38. The relationship of TRM and TCM is unclear, but both express low levels of 
KLRG-16, a molecule strongly expressed by effector and TEM cells. These data, in addition 
to a recent report demonstrating TRM and TCM clones sharing the same variable sequence 
(CDR3) of the T cell receptor38 suggest that there is a common precursor of TRM and TCM. 
With regard to the balance of TRM and TCM, a recent report suggested that the mTOR 
pathway may regulate this balance, since mTOR inhibitors like rapamycin favor TCM 
generation in mouse models39. Another recent study suggested that high expression of the 
transcription factor T box specific protein 21, or T-bet, favored TEM over TRM 
differentiation, while lower expression of this protein was found in TRM 40.
While TRM are most likely to have evolved to protect us against infection from dangerous 
environmental pathogens, normal flora of tissue microbiomes, as well as innocuous 
environmental proteins, can all give rise to TRM. A recent report in mice found that allergic 
contact dermatitis was mediated by TRM that had been generated in response to a topically 
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applied allergens as well as a protein plus adjuvant38. TRM were described as early as 
200141, and this same group demonstrated that TRM in gut did not recirculate between 
parabiotic mice, in contrast to T cells in lymph node and spleen42.
Common features of Trm in barrier tissues
Homing of TRM
TRM are characterized by their inability to re-circulate between tissue, lymph node, and 
blood4,43–47, although understanding the factors that help them achieve this is an active area 
of research. The glycoprotein CD69 is a marker of TRM, and is expressed on TRM in skin, 
lung, GI tract, and everywhere TRM have been identified4–6,28,48–50. CD69 was originally 
thought to be a marker of recent T cell activation in the lymph node;51 however most TRM in 
tissues are at rest. CD69 appears to be involved in peripheral tissue retention of TRM which 
appears to involve the downregulation of the G protein coupled receptor for sphingosine 1 
phosphate (S1P1)52. There is a gradient of levels of sphingosine 1 phosphate in the body in 
humans and mouse, with the lowest levels in peripheral tissue, intermediate levels in lymph 
node, and the highest levels in blood50,53,54. These S1P gradients normally function to guide 
T cells out of tissues to lymph node, and out of lymph nodes into blood. Expression of CD69 
by TRM interferes with cell surface expression and function of S1P1, thus blocking the 
capacity of these T cells to sense S1P gradients and supporting their stationary nature50. The 
transcription factor Kruppel-like Factor 2, which normally enhances S1P1 expression, is 
downregulated in TRM, thus indirectly enhancing CD69 expression 53. The mechanism by 
which CD69 and S1P1 compete with each other for cell surface expression is not completely 
understood54.
The chemokine receptor CCR7 is another G protein coupled receptor that senses molecular 
gradients of its ligands CCL19 and CCL21, and directs T cells and dendritic cells from skin 
to lymph node via afferent lymphatics55. Expression of CCR7 allows T cells to migrate in 
response to gradients of its chemokine ligands, which are normally not abundant in tissue 
but are at their highest levels in lymph node and afferent lymphatics. It was recently shown 
in a mouse model that CD4+ T cells in skin require CCR7 to migrate to afferent lymphatics, 
and that blocking CCR7 expression prevented T cells from leaving skin56. In human skin, 
expression of CCR7 was seen on a population of T cells that migrated out of skin (so called 
T migratory memory or TMM cells), while CCR7− T cells remained in skin as TRM57. The 
relative contributions of S1P1 and CCR7 expression on T cells to migration out of tissues 
have not been determined.
The integrin CD103 (also known as αE, and which pairs with β7) is another marker of TRM; 
however, its expression is more predominant on CD8 than CD4 TRM. It is a known ligand of 
E-cadherin, a homotypic adhesion molecule expressed by epithelial cells in barrier tissues58. 
In mouse models, CD8 T cells specific for HSV-1 enter the skin lacking CD103 expression, 
and then in response to epidermal TGFβ upregulate CD1036. CD103 is also found expressed 
by TRM in the lung and GI tract, and even in TRM in the brain upon CNS viral 
infection7,40,48,59. It is tempting to assume that αEβ7 on these cells is binding to epithelial 
cells via interactions with E cadherin. However, binding to E cadherin is not required for 
tissue residence, as CD103+ CD4 and CD8 TRM can be found in the dermis, and CD103+ 
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dendritic cells are plentiful in the dermis without ever entering the epidermis60. While E 
cadherin is expressed during brain development, it is absent in adult CNS tissue61, despite 
abundant CD103 on brain CD8 TRM. Thus while its role is incompletely understood, it does 
appear that CD103 expression is a marker of differentiation of TRM6 rather than a functional 
requirement for tissue residence. It is notable that CD103 TRM have less proliferative 
potential and more significant effector cytokine production capacity than CD103− T cells in 
several human and mouse models7,40,41,48,59,62,63. CD103 expression is also not a strict 
requirement for human skin cells being TRM 57. A recent report suggested that CD103− TRM 
may play a different role in gut in a mouse model, being generated in inflammatory 
microenvironments in the lamina propria and playing a unique role in controlling 
infection64.
Less is known about CD4 TRM than CD8 TRM in part because these cells are less efficiently 
generated by viral infection in mouse models in which TRM have been most completely 
characterized. Studies of HSV infection of the female mouse reproductive tract suggest that 
local chemokine gradients from tissue mononuclear cells maintain CD4 TRM in place37. In 
skin, evidence suggests that CD4 TRM do not preferentially localize to the epidermis, and 
express lower levels of CD103 than CD8 T cells4,63. HSV specific CD4 T cells in mouse 
skin may be more mobile than CD8 TRM, and limited to the dermis65. CD4 T cells in skin 
may express CCR7 and/or CD69 5,56. In a recent study the authors treated highly 
immunocompromised NOD/Scid/IL-2Rγ-deficient (NSG) mice bearing human skin 
xenografts with alemtuzumab (an antibody that binds human CD52, a molecule present on 
all T cells). This humanized antibody has been shown to deplete human T cells in blood but 
not tissue57,66. Two populations of CD4 T cells could be isolated from skin of these mice: 
those that expressed both CCR7 and L selectin (markers of TCM), and those that expressed 
CCR7 but not CD69 (dubbed T migratory memory, or TMM by this group). The two 
populations of CD4 T cells that remained within the skin both expressed CD69 and lacked 
CCR7 (and were thus unresponsive to S1P and CCL19/21 gradients), and contained 
CD103+ and CD103− populations. Thus, four distinct populations of CD4 T cells could be 
identified in human skin, two of which were short term residents and could exit skin into 
blood, and two that were true TRM57.
Maintaining TRM in tissues
The molecular factors that maintain TRM in their resident tissue are less well understood, but 
IL-15 TGFβ, TNFα, and IL-33 have all been implicated in maintenance of TRM 6,53. TGFβ, 
TNFα, and IL-33 have all been shown to have a role in induction of CD103 expression and 
acquisition of a TRM phenotype. Factors that upregulate CD69 include TNFα and type I 
interferons50,67. The aryl hydrocarbon receptor is important for maintenance of γδ T cells in 
mouse skin68, and a recent report suggests that it is important for the generation of αβ TCR 
CD8 TRM 69. A recently described additional common activity of CD8 TRM was highlighted 
by several recent papers. One of the first cytokines made by CD8 TRM upon antigen 
reactivation is IFNγ. In both skin and reproductive mucosa, the IFNγ released by reactivated 
TRM created a generalized anti-viral microenvironment in tissue, by upregulating a series of 
antiviral and antimicrobial genes from keratinocytes, enhancing vascular adhesion molecule 
expression endothelium, and activating other resident cells including NK cells and dendritic 
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cells70,71. In this fashion, TRM can amplify and activate the innate immune system, creating 
an environment inhospitable for even completely unrelated viruses and other pathogens.
Properties of Trm in distinct barrier tissues
Skin TRM
In 2006, it was discovered that normal resting human skin contained twice as many T cells 
as blood5,72,73, and it is now appreciated that the majority of these cells are TRM57. Thus, 
memory T cells previously generated in response to pathogens in the cutaneous environment 
are present in abundance in the skin, allowing for immediate response to pathogenic 
invasion5. These cells have a diverse T cell receptor repertoire and can be activated by 
pathogens at a much lower threshold than circulating T cells via the T cell receptor72. 
Moreover, they are heterogeneous; they include CD4+ and CD8+ T cells that produce IL-17, 
IFNγ, TNFα, IL-9, IL-13, and other cytokines, alone or in combination5,32,72–76.
Human peripheral blood T cells enriched in skin (CLA), gut (α4β7), or lung (CLA/α4β7-) 
tropic memory T cells are specific to previously encountered pathogens of those tissues32. 
Mouse models have been instrumental in our understanding of skin TRM. Early studies 
showed that mice transfused with transgenic T cells specific for HSV peptides, and then 
infected with HSV, showed that HSV specific CD8 T cells could be transferred from one 
mouse to another by a previously infected skin graft, and that these cells maintained their 
ability to clear virus upon challenge63. In another study it was shown that skin scarification 
by vaccinia virus (VACV) was far superior to other routes of immunization in generating 
skin resident CD8 T cells77. These investigators also showed that skin TRM, in the absence 
of TCM and antibody, could clear virus on re-challenge. Furthermore, skin scarification 
generates lung TRM that, in the complete absence of circulating antibodies and TCM can 
partially protect naive mice from an otherwise lethal pulmonary challenge with VACV77. 
Thus, skin immunization can lead to widespread TRM throughout skin and also in distant 
barrier tissues. Another study showed that after HSV challenge in mice, CD8+ TRM migrate 
to the epidermis and acquire a sessile phenotype, while CD4+ TRM localize to the dermis 
and show greater mobility65. This is not only at the site of infection, but also at distant sites, 
and more CD8 TRM accumulate throughout the skin after multiple infections at distinct 
sites 4. However, CD8 TRM do not re-circulate, and mice that contain TCM but lack TRM are 
cannot effectively clear VACV from skin, in contrast to mice that have immune skin TRM 4.
Interestingly, TRM from skin, lung, and gut have transcriptomes that have common core 
features in mouse6. This same study showed that localization of CD8+ TRM in the epidermis 
and CD103 expression of TRM was induced in the epidermis by TGFβ, these CD8+ TRM 
cells homed to epidermis by an uncharacterized chemokine mediated process6. Mouse CD8 
TRM were also shown to occupy epidermal niches formerly filled by a population of T cells 
that seed the epidermis prior to birth--γδ Dendritic Epidermal T Cells--, and when viewed by 
intravital microscopy moved laterally between keratinocytes, unlike sessile γδ DETC. These 
CD8 TRM interacted transiently with Langerhans cells, suggesting that they were scanning 
the environment for antigen 69. In humans, there are two isoforms of the dimeric CD8 
molecule on T cells, composed of αβ or αα chains, respectively. After cutaneous HSV 
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infection, CD8αα TRM localize at the dermal epidermal junction. These cells, but not 
CD8αβ T cells, protected against reactivation of HSV and lesion formation78.
Somewhat less is known about CD4 skin TRM in mice than about CD8 skin TRM. It has been 
shown, however that CD4 Treg are a major population of T cells emigrating from skin to 
lymph node after an immune response to contact hypersensitivity, as well as in the absence 
of stimulus79. Another group characterized CD4 T cells in mouse skin, and demonstrated at 
least two populations, one that did not leave skin (lacking expression of CCR7), and another 
that left skin by a CCR7-dependentmechanism and expressed low levels of CD62L, high 
levels of E selectin ligand, and was negative for CD6956. This is consistent with a very 
recently published study from human skin57.
TRM in the GI tract
TRM in gut are defined here as T cells that reside in the epithelium or in lamina propria80. It 
has been shown that a subset of CD103+ dendritic cells in gut draining lymph node can 
skew naive T cells toward differentiation into α4β7 gut homing memory T cells, primarily 
under the influence of TGFβ secreted by these DCs81. Gut infiltrating T cells have been 
most exhaustively studied in mice during disease states, such as experimentally induced 
colitis, in which mice lacking CD103 had attenuated inflammation suggesting a role for TRM 
in inflammation. Less attention has been paid to TRM that emerge after pathogen infection, 
until very recently48,70. Several infections, including lymphocytic chorionomeningitis virus, 
listeria, and others have been shown to generate long lived intraepithelial T cells with potent 
effector activities in mice 42. While many of these infections were delivered intravenously, 
in a recent study mice were infected orally with Listeria to study gut TRM48. This study 
found that long lived gut TRM express KLRG-1 at low levels (consistent with skin TRM), 
while cells that highly expressed KLRG-1 (as in TEM) and entered gut underwent apoptosis. 
This oral immunization induced abundant long lived gut TRM, unlike nasal immunization 
which induced entry T cells highly expressing KLRG-1 into gut that did not persist long 
term. Gut CD8 TRM expressed CD69 and CD103, as do mouse skin TRM, and their 
maintenance in the gut was enhanced by TGFβ80. When transcriptional profiles of skin TRM 
generated by HSV infection were compared to gut TRM induced by an LCMV infection6, of 
127 genes up or down regulated in TRM in comparison to TCM, 68 showed a pattern 
common to skin and gut, and the remainder were unique to gut (or possibly to the difference 
between LCMV and HSV infection) 6. Thus, the TRM that form in gut epithelium and 
lamina propria bear many features common to TRM in other barrier tissues, although they 
express gut-specific homing molecules.
As regards what is known about gut TRM in humans, a recent study that surveyed resident T 
cell populations in various human tissues demonstrated the presence of TRM in both colon 
and small intestine82. We have further analyzed human GI tissue by deep sequencing of 
TCRBV1 and identified a highly diverse T cell repertoire in normal tissue (data not shown). 
Liver TRM have been demonstrated after malaria infection83, and the T cells that infiltrate 
the liver during viral hepatitis likely become tissue resident as well, causing significant 
tissue injury in the absence of effective therapy84.
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TRM in Lung/respiratory tissue
The possibility that TRM cells might exist in lung stemmed from the identification of CD69+ 
CD8+ TRM cells that remained in lung after influenza infection28. The previous explanation 
of the expression of CD69 was that they were in an activated state, perhaps as a result of 
retained antigen; however, we now know that CD69 expression is a generic characteristic of 
resting TRM.29 There is good evidence that CD8+ resident memory T cells can be protective 
against subsequent infection with influenza. Intranasal, but not intraperitoneal infection with 
influenza in mice results in the presence of lung TRM, though both routes of infection 
efficiently produced influenza-specific TEM30. Furthermore, the nasal influenza immunized 
mice, but not the intraperitoneally immunized mice, are protected against a lethal intranasal 
challenge with influenza. This echoes the work in skin showing that resident, but not 
circulating, memory T cells are most effective at limiting viral replication at the site of viral 
entry4. However, in this lung infection study the TRM had essentially vanished from lung 90 
days after a single influenza infection. Whether they could be made more abundant at this 
late stage after boosting strategies such as additional antigen challenge was unexplored.
The anatomic location within the lung where TRM need to reside to be most protective 
against a flu challenge is also controversial -it is clear that lung TRM express CD103, and its 
epithelial ligand, E-cadherin, is most strongly expressed on large and intermediate bronchial 
epithelial cells and less so on small or alveolar epithelia85. However, as discussed above, 
CD103+ cells can persist at a distance from E cadherin expressing cells. As regards the 
levels of CD4+ vs. CD8 + T cells TGFβ promotes the development of lung CD103+ CD8+ 
TRM cells, but in a fashion not dependent on Smad486. CD4+ T cells in lung help to develop 
CD103+ CD8+ TRM cells after influenza virus infection40, but the relative roles of CD4 and 
CD8 T cells, and whether (as in skin) these two populations have different migratory 
capacity, have not been explored.
There is a growing body of evidence that points to the existence of TRM in normal human 
lung, though this tissue is difficult to obtain. While T cells have been observed in 
bronchialveolar lavage samples, these are typically done in the setting of diseased lung, and 
thus it is not known whether they are authentic TRM. Pneumonectomies from human lung 
derived from tissue very distal tumors is regarded as normal 87 and T cells isolated from 
such normal lung samples produce TNFα and IFNγ87. They also express CD69, their TCR 
repertoire is diverse, and from these data it is estimated that the number of TRM in lung 
approximated the number of T cells in blood, on the order of 10 billion cells. Moreover, 
these populations of T cells are enriched in the cells that proliferate in response to 
inactivated influenza87. Lung TRM express abundant α1β1, though this is expressed in other 
tissues and is thus not lung-specific87. CD8+CD103+ T cells in human lung were specific 
for influenza, rather than CD8+ CD103− T cells which are also found59. TRM in human lung 
were also demonstrated in a large survey study that looked at multiple human tissues82.
Genitourinary tract
The mucosa of the female reproductive tract is an important barrier tissue. In mouse HSV 
infection, CD4 T cells must first enter the tissue and provide a recruiting cytokine and 
chemokine signal to facilitate entry of CD8 T cells into infected vaginal mucosa34. This is 
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different from skin, in which CD4 help is not required to recruit antigen specific CD8 T cells 
after VACV infection4. Protective immunity against HSV can also be generated by direct 
topical infection of the vaginal mucosa followed by accumulation of TRM 35, suggesting the 
generation of TRM should be a goal of vaccination88. Analogous work was performed 
independently, comparing skin and mucosa with HSV infection36. Approaches like these are 
likely to be attempted to generate a protective vaccine against HSV-2. Very recently, it was 
shown that a local chemokine gradient maintained HSV specific CD4 cells in situ, a novel 
mechanism for maintenance of TRM residence89. Furthermore, it was recently shown that 
the HPV vaccine delivered to mice intravaginally generated CD8+ TRM in vaginal 
mucosa90,91. This work is very promising, since not only HSV and HPV, but also HIV can 
infect through this route, and the possibility of rapidly killing virally infected cells with 
TRM, however generated, is appealing (box 1)88. More recently, work on cervical tissue—
normal, dysplastic, and malignant—has demonstrated that vaccination against oncogenic 
papilloma virus generates TRM in these tissues which are highly protective against 
reinfection 92.
Box 1
Cancers of Skin Resident T Cells
TRM’s and cancer. Certain skin lyphomas appear to be malignacies of skin TRM. Tumor 
infiltrating lymphocytes have features of TRM. Infiltration of tumors by T cells appears 
to be associated with a positive response to immune checkpoint blockade drugs, such as 
antibodies to PD-1, PD-L1, and CTLA4.
Cutaneous T Cell Lymphomas (CTCL) are a heterogeneous group of rare malignancies 
of T cells118. Recent reports have supported the idea that one form of this disease, 
mycosis fungoides (MF), is a malignancy of CD4+ TRM from skin66,98. MF forms 
patches and plaques on the skin with well demarcated borders, and tends to recur in 
precisely the same locations after remission. It is responsive to skin directed therapy in its 
early stages118. The malignant T cell does not express CD62L, is CLA+ and CCR4+, and 
often expresses CD6966. In advanced stages, T cells can travel to distant skin sites or to 
lymph node. It is not known whether this represents acquisition of markers such as CCR7 
(which facilitate exit from skin) or a malignant de-differentiation program that reduces 
skin tropism119. The other most common type of CTCL is leukemic CTCL, often called 
Sezary Syndrome98. In these patients, skin lesions are typically characterized by 
confluent erythema, also known as erythroderma, and lesions do not have well defined 
borders. Malignant T cells are found in skin as well as blood, and sometimes lymph node. 
The malignant cells bear not only skin homing markers (CLA, CCR4) but also TCM 
markers (CD62L, CCR7). The humanized antibody alemtuzumab depletes CD52+ cells, 
including the malignant T cell clone, in blood, a process largely mediated by neutrophil 
and NK ADCC66. However, even though alemtuzumab binds to T cells in skin, it does 
not deplete them. Interestingly, alemtuzumab has absolutely no efficacy in MF, 
supporting the idea that MF T cells are TRM and do not traffic into blood from skin66. It 
has very high efficacy in L-CTCL, a malignancy of recently described skin homing 
TCM57,119.
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TRM in solid tumors. We have proposed that T cells that enter tissue acquire the TRM 
phenotype, characterized by a unique transcriptional profile including expression of 
CD69 and CD103 (particularly on CD8 T cells), and downregulation of KLF-2 and S1P1. 
The infiltration of tumors, or peritumoral tissue, with T cells (so called tumor infiltrating 
lymphocytes or TILs) is associated with a better long term response120. One recent study 
suggested that such infiltration predicted response to immunotherapy with antibodies to 
PD-1121. CD103 expression on TRM in ovarian cancer predicts a more favorable 
prognosis122, and analogous results were recently seen in lung cancer123. Thinking of T 
cells entering tumors or peritumoral tissue as having a TRM phenotype may be a useful 
way of conceptualizing these cells. Expression of inhibitory molecules like PD-L1 on 
tumor stroma, or production of other immuosuppressive factors will blunt the activity of 
these tumor specific TRM. However, antibodies to PD-1 and PD-L1 suggest that 
activating these T cells may be a very useful way of activating immune mediated tumor 
destruction112,121.
The role of TRM in human disease
Pathologic TRM in non-barrier tissues
The best characterized role for TRM in disease is in mediating skin diseases, with fixed drug 
eruption being the first and best described93. More recently, established psoriasis has been 
shown to be mediated largely by TRM. Transcriptomic analysis of resolved lesional psoriatic 
skin in humans reveals the presence of T cells and cytokines thought to be important in the 
pathogenesis, suggesting the residence of these TRM cells 94,95. Even more recently, analysis 
of cells extracted from resolved psoriatic lesions revealed CD8+ T cells that produce IL-17 
and CD4+ T cells that produce IL-22, providing additional proof for the role of TRM in 
psoriasis96. A recent report demonstrated that allergic contact dermatitis (ACD) in both 
human and murine settings is also TRM mediated38. In psoriasis, the antigen is considered to 
be autoantigen, while in ACD it is often an innocuous environmental molecule97 and in 
fixed drug eruption a chemical. Lesions in psoriasis that are treated, resolve, and then recur 
in the same place suggest that while the activity of disease-causing TRM was suppressed by 
therapy, their localization was unaffected. Vitiligo, as well as some forms of atopic and 
eczematous dermatitis may also be TRM mediated5; here the antigen is a melanocyte specific 
antigen. Interestingly, a variant of Cutaneous T Cell Lymphoma was found to be a 
malignancy of TRM98 while another variant (Leukemic CTCL/Sezary syndrome) is a 
malignancy of skin homing TCM 66,98(see box 2).
Box 2
TRM and vaccination
TRM and Vaccines. It is known that TRM are highly protective against pathogens that 
have been encountered previously. Increasingly, vaccine approaches that target the 
generation of TRM in the tissue likely to be infected by the pathogen are being 
considered.
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The observation that pathogenic virus can be rapidly eliminated by TRM in animal 
models, even in the absence of antibody, has led to a burgeoning interest in the induction 
of TRM as a goal of vaccination4,77. Viruses show tissue tropism, with influenza specific 
for lung, rotavirus specific for gut, and HSV specific for skin and other stratified 
squamous epithelia. TRM based vaccination would direct pathogen specific TRM to the 
relevant epithelial tissue88. Currently, the titer of neutralizing antibodies generated by a 
vaccine is considered a proxy for its efficacy. But for viruses invading barrier tissues, 
infection of a resident cell and subsequent hijacking of the cells program to make more 
virus is largely insensitive to extracellular antibody. In contrast, such infected cells 
express viral peptides on cell surface class I molecules, making CD8 TRM’s. Vaccination 
at epithelial surfaces, rather than intramuscularly, is thus an effective way to generate 
robust TRM’s30,48,77,91. Promising approaches in lung for influenza and in other mucosal 
tissues have been recently reported39,40.
Proof of principle in animal models for Vaccinia vaccinations of skin and lung, influenza 
vaccinations of lung, and Listeria immunization through oral administration have all 
shown generation of highly effective tissue resident TRM’s. A recent HIV vaccine 
engineered to generate effector memory T cells showed great promise, and while the 
investigators focused on blood they did find memory T cells in mucosal tissue124. The 
wisdom of generating lung TRM specific for conserved portions of the influenza virus, or 
anogenital mucosal TRM specific for conserved portions of HIV, is clear. Virally infected 
cells could be targeted by TRM for elimination shortly after exposure. The challenge with 
this approach to vaccination is at the level of practicality—how to immunize through an 
accessible tissue (like skin) and generate TRM in tissues that are specific to the infectious 
virus. One of several promising approaches involves using Vaccinia vectors delivered by 
skin scarification—this has been shown to generate lung TRM in one model. Also, 
because skin immunization in general generates both skin TRM and a TCR identical 
population of TCM in lymph node38, sequential skin and peripheral tissue immunization 
(to convert the TCM into tissue relevant TRM) is a possible approach. While most work on 
TRM’s has been done in the setting of viral infection, this approach should be applicable 
to other tissue selective pathogens. Mycobacterium tuberculosis, Listeria, Cholera, and 
M. Leprae are all candidate pathogens. What remains to be understood is what collection 
of factors in regional lymph nodes govern the acquisition of tissue homing markers on 
effector T cells, and how to ensure that these T cells that enter tissue remain as long lived 
TRM, poised to respond to pathogens through the appropriate environmental interface88.
The GI tract is another site where certain diseases exhibit the behavior of TRM mediated 
diseases. The discrete waxing and waning skip lesions –areas of disease separated by areas 
of normal mucosa--in Crohn’s disease suggest a role for TRM, while ulcerative colitis 
involves a more contiguous circumferential area of the large intestine99. It is unknown, 
however, whether immune mediated diseases of the lung (i.e., asthma) involve TRM. There 
is no data that addresses this possibility, though the presence of TRM in normal lung makes 
the hypothesis a reasonable one. Certainly, the excessive inflammation in lung in the setting 
of fatal influenza infection may well involve hyperactive TRM. Additionally, that T cell 
mediated diseases of the skin are mediated by TRM, and that these diseases can often be 
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treated with skin-directed rather than systemic therapy, suggests that this approach of local 
rather than systemic treatment may apply to other tissues as well.
Pathologic Trm in non-barrier tissues
It has been shown experimentally that accumulation of TRM can also occur in tissues 
generally considered to be sterile, such as the brain7. TRM were identified in the brain after 
intranasal infection with vesicular stomatitis virus, and CD103+ TRM had a potent effector 
function after in vitro stimulation. The transcriptional profile of these brain CD8 TRM 
resembled that of TRM in skin, gut and lung6,7. Whether such TRM can form in human brain 
after viral infection is unknown, and a putative role for these cells in diseases of the CNS 
requires additional evidence, though recent reports have linked putative pathogenic brain 
TRM to multiple sclerosis and even schizophrenia.100,101 While T cell responses in non-
barrier tissues may be necessary episodically to deal with a potentially lethal infection, the 
unintended consequence of such an event may be the generation of long lived TRM and 
predisposition to potential autoreactive and autoimmune diseases. One hypothesis is that the 
program to generate TRM exists in all activated T cells, and that a subset those that gain 
entry into tissue (whether a barrier tissue or a normally sterile tissue) show activation of this 
program.
Spondyloarthropathies such as human ankylosing spondylitis involve inflammation of 
enthesial tissues (attachment of tendon to bone) and one recent study demonstrated enthesial 
resident Th17 TRM to be essential for disease progression102. In human rheumatoid arthritis, 
the clinical recurrence of disease in individual joints bears the hallmarks of a TRM driven 
process, and a preliminary report describes the presence of TRM in human joint synovium in 
rheumatoid arthritis 103. Sterile chronic inflammation of peripheral tissues in human disease 
is thus probably often mediated by these cells. For example, T cells from blood and kidney 
were examined in lupus nephritis, and a relatively limited set of T cell clones appeared to be 
responsible for progressive disease in individual patients, even over periods separated by 
months to years104. While this study did not examine CD103 or CD69, it provides indirect 
proof for pathological renal TRM. In murine models of insulin dependent diabetes mellitus 
and pancreatic islet β cell rejection, infiltrating CD8 T cells acquire CD103 and remain in 
place during the immune response105. In the pancreas, it is conceivable that in human type 1 
diabetes mellitus, T cells that infiltrate pancreas and attack β cells may take on the 
phenotype of TRM, thus favoring their long term persistence in situ. In solid organ allograft 
rejection, infiltrating allogeneic T cells are able to acquire TRM properties like CD103 
expression106, and urinary CD103 is associated with acute graft rejection107. If these human 
diseases involve pathological TRM, immunosuppressive regimens may suppress their 
activation, but will not affect their location and persistence, thus setting the stage for 
recurrence and persistence of disease.
Finally, there is evidence that some tissues of immune privilege, like the eye, may have 
mechanisms to inactivate TRM produced by inflammation108, by expressing PD-LI and 
promoting T cell PD-1 expression109. Through mechanisms that are still unclear, cancers are 
also tissues of relative immune privilege. Binding of T cell PD-1 to its natural ligand PD-L1 
induces a state of T cell unresponsiveness, and recently therapeutic antibodies to PD-1 have 
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been used in metastatic melanoma to interfere with this unresponsiveness and to augment 
the antitumor response. Tumor infiltrating lymphocytes by definition become “resident” to 
neoplastic tissue. It is notable that TIL with surface markers of TRM were found to predict a 
more favorable prognosis in ovarian cancer110. The role of PD-1 PDL-1 interactions 
suppressing the activity of TIL’s is now well established111,112
Conclusions
Barrier tissues at interfaces with the environment TRM are an important part of the adaptive 
immune system, providing the capacity to rapidly address and clear infections from 
previously encountered pathogens. When these cells pathologically accumulate in barrier 
tissues, in response to innocuous antigens, human disease can result. The molecular program 
that facilitates the TRM phenotype in barrier tissues can be activated in other tissues as well, 
where persistent immune driven inflammation can cause chronic human disease. Regardless 
of the tissue involved, when T cells are seen in pathologic infiltrates, it was previously 
assumed that this represented chronic and dynamic T cell infiltration. It is more than a 
semantic difference to propose that these infiltrates in fact represent resident populations of 
T cells in which a TRM molecular program has been activated. If this is the case, therapies 
that suppress T cell function will not necessarily change T cell localization, and reactivated 
TRM will mediate recurrent disease. Whether in CNS, joint, pancreas, kidney, or heart, 
persistent and activated TRM in tissues (where they were never intended to be) may drive 
human diseases. Therapies directed at selectively eliminating these TRM, by depletion or by 
modifying their ability to persistently reside in tissue, represent novel approaches to the 
treatment of such diseases.
It is worth noting that skin TRM have been unknowingly targeted for decades, far before the 
appreciation that these cells existed. Skin directed therapies, ranging from topical 
corticosteroids to UV-based phototherapy, to low dose radiation have all led to remission of 
what are now understood as TRM mediated diseases. Would gut mucosal directed therapy 
via endoscope, or synovial directed therapy via arthroscope, suppress TRM in those tissues? 
The advantage of skin targeted therapy is that repetitive therapy is straightforward and non-
invasive, and the results to not require sophisticated imaging to assess. Other approaches 
might be directed at features that maintain TRM in tissue, namely therapies that target CD69 
and CD103. Blocking or interfering with the function of these molecules might flush 
pathogenic TRM out of tissues, and of course a balance would have to be struck between 
depleting pathogenic TRM and physiologically protective normal TRM. Finally, it was noted 
that TRM in immune privileged sites like the eye express PD-1, and presumably remain 
quiescent in this fashion. We speculate that tumor TIL’s are a form of TRM, and the tumor 
may induce PD-1 on these TRM to suppress their activity. If this suppressive pathway could 
be exploited in diseases where unrestrained TRM activity causes tissue inflammation and 
injury, yet another approach to suppressing disease-causing TRM would exist. None of these 
approaches (save those long employed in skin) are more than hypothetical at present. 
However, what is clear is that while simply suppressing the activation of TRM in psoriasis, 
inflammatory bowel disease, or inflammatory arthritis may lead to transient remission, 
recurrence of disease is nearly inevitable if TRM persist (as they are designed to do) in 
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tissue. The next decade of TRM biology will be devoted to modifying their behavior and, 
perhaps, their location.
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Figure 1. 
A. Upon first encounter with pathogen in barrier tissues, dendritic cells carry antigen to 
draining lymph nodes and present to naive T cells. Depending on the anatomic location of 
the lymph node, trafficking molecules (indicated adjacent to the lymph) are expressed on the 
expanding activated T cell population, and effector T cells with specific tissue homing 
properties preferentially exit blood in peripheral tissues. Gut draining lymph nodes induce 
the expression of gut homing molecules on gut homing T cells, while skin draining lymph 
nodes induce the expression of skin homing molecules on skin homing T cells. Analogous 
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processes occur in lymph nodes draining lung and reproductive mucosa. B. Long after the 
pathogen has been eliminated from the barrier tissue and inflammation has resolved, 
populations of TRM remain behind in each of these tissues. These TRM retain the tissue 
homing molecules originally imprinted on them, and acquire a molecular program that 
contributes to maintaining these cells in peripheral tissue. In parallel, circulating memory T 
cells are generated, and these have the capacity to enter lymph node and recirculate into 
blood and tissue. Some evidence suggests that the same naive T cell may give rise to both 
the TRM and the TCM or circulating T cell.38
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Figure 2. 
The Role of TRM in Tissue specific autoimmune and inflammatory disease. Left panels; 
diseases of skin, gut, and lung clearly or potentially mediated by inappropriately activated 
TRM. Right panels; diseases of normally sterile non-barrier tissues mediated by infiltrating T 
cells that have acquired the properties of TRM.
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